273 related articles for article (PubMed ID: 27931793)
61. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
Prabhu V; Foo J; Ahir H; Sarpong E; Merchant S
J Med Econ; 2017 Aug; 20(8):840-849. PubMed ID: 28532194
[TBL] [Abstract][Full Text] [Related]
62. Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.
Smith JR; Arya A; Yim J; Barber KE; Hallesy J; Singh NB; Rybak MJ
Antimicrob Agents Chemother; 2016 Jul; 60(7):3970-5. PubMed ID: 27090172
[TBL] [Abstract][Full Text] [Related]
63. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae.
Titelman E; Karlsson IM; Ge Y; Giske CG
Diagn Microbiol Infect Dis; 2011 May; 70(1):137-41. PubMed ID: 21513849
[TBL] [Abstract][Full Text] [Related]
64. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.
Chandorkar G; Huntington JA; Gotfried MH; Rodvold KA; Umeh O
J Antimicrob Chemother; 2012 Oct; 67(10):2463-9. PubMed ID: 22773741
[TBL] [Abstract][Full Text] [Related]
65. Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against Escherichia coli clinical isolates.
Sumi CD; Heffernan AJ; Naicker S; Cottrell K; Wallis SC; Lipman J; Harris PNA; Sime FB; Roberts JA
J Antimicrob Chemother; 2022 Oct; 77(11):3026-3034. PubMed ID: 36031790
[TBL] [Abstract][Full Text] [Related]
66.
Mazer DM; Young C; Kalikin LM; Spilker T; LiPuma JJ
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674053
[TBL] [Abstract][Full Text] [Related]
67. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection.
Strayer AH; Gilbert DH; Pivarnik P; Medeiros AA; Zinner SH; Dudley MN
Antimicrob Agents Chemother; 1994 Oct; 38(10):2351-6. PubMed ID: 7840569
[TBL] [Abstract][Full Text] [Related]
68. Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications.
Tamma SM; Hsu AJ; Tamma PD
Paediatr Drugs; 2016 Feb; 18(1):1-11. PubMed ID: 26645401
[TBL] [Abstract][Full Text] [Related]
69. Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infections.
Giancola SE; Mahoney MV; Bias TE; Hirsch EB
Ther Clin Risk Manag; 2016; 12():787-97. PubMed ID: 27279744
[TBL] [Abstract][Full Text] [Related]
70. Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model.
Islam K; Sime FB; Wallis SC; Bauer MJ; Forde BM; Harris P; Shirin T; Habib ZH; Flora MS; Roberts JA
J Antimicrob Chemother; 2022 Aug; 77(9):2448-2455. PubMed ID: 35724128
[TBL] [Abstract][Full Text] [Related]
71.
Robin F; Auzou M; Bonnet R; Lebreuilly R; Isnard C; Cattoir V; Guérin F
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914962
[TBL] [Abstract][Full Text] [Related]
72. Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum β-lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model.
Zhanel GG; Denisuik A; Vashisht S; Yachison C; Adam HJ; Hoban DJ
J Antimicrob Chemother; 2014 Sep; 69(9):2448-52. PubMed ID: 24827891
[TBL] [Abstract][Full Text] [Related]
73. Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections.
Skalweit MJ
Drug Des Devel Ther; 2015; 9():2919-25. PubMed ID: 26082619
[TBL] [Abstract][Full Text] [Related]
74. Unusual tazobactam-sensitive AmpC beta-lactamase from two Escherichia coli isolates.
Babini GS; Danel F; Munro SD; Micklesen PA; Livermore DM
J Antimicrob Chemother; 1998 Jan; 41(1):115-8. PubMed ID: 9511046
[TBL] [Abstract][Full Text] [Related]
75. Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections.
Larson KB; Patel YT; Willavize S; Bradley JS; Rhee EG; Caro L; Rizk ML
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962340
[TBL] [Abstract][Full Text] [Related]
76. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
Gentile I; Maraolo AE; Borgia G
Expert Rev Anti Infect Ther; 2016 Oct; 14(10):875-8. PubMed ID: 27599088
[No Abstract] [Full Text] [Related]
77. Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model.
VanScoy BD; Mendes RE; Castanheira M; McCauley J; Bhavnani SM; Jones RN; Friedrich LV; Steenbergen JN; Ambrose PG
Antimicrob Agents Chemother; 2014 Oct; 58(10):6024-31. PubMed ID: 25070105
[TBL] [Abstract][Full Text] [Related]
78.
Teng JLL; Chan E; Dai ACH; Ng G; Li TT; Lai C; Wu AKL; Lau SKP; Woo PCY
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0122421. PubMed ID: 34662198
[TBL] [Abstract][Full Text] [Related]
79. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
Pitout JD; Le P; Church DL; Gregson DB; Laupland KB
Int J Antimicrob Agents; 2008 Oct; 32(4):333-8. PubMed ID: 18701262
[TBL] [Abstract][Full Text] [Related]
80. Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam.
Lister PD; Prevan AM; Sanders CC
Antimicrob Agents Chemother; 1997 Apr; 41(4):721-7. PubMed ID: 9087477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
